



09/865321

D0028 NP

C9C

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nickki L. Parlet  
Type or print name

*Nickki L. Parlet*  
Signature

October 6 2006  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF  
**ROBERT PEACH, ET AL**

PATENT NO: 7094874

FILED: 05/23/2001

FOR: **SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF**

**REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT**

FOR PTO MISTAKE (37 C.F.R. §1.322(a))

Sir:

Attached, in duplicate, is Form PTO-1050, with at least one copy being suitable for printing.

Certain errors occurred through the fault of the USPTO, for which correction is sought under 37 CFR 1.322. These errors can be seen in the attached Form PTO-1050.

The exact pages and line numbers where the errors occurred are:

Column 37, line 44 and 48

"extraceilular" should read --extracellular--

Column 37, line 46

"methionirie" should read --methionine--

Column 39, line 40

"praline" should read --proline--

Column 40, line 3

"CD86than" should read --CD86 than--

**Certificate**  
**OCT 13 2006**  
**of Correction**

**OCT 16 2006**

Page 1, Column 2, under "Foreign Patent Documents"

The following patents should be added:

--WO 01/90122 A2--

--WO 01/54732 A1--

--WO 00/23115--

--WO 96/14865--

Page 2, Column 1

The following publication should be added, between Exhibit 49 and Exhibit 51:

--Rajesh et al. (1998) Pharm Sci Supplement S-535. (Exhibit 50)--

Page 3, Column 2

"Exhibit 188" should read --Exhibit 118"--

Page 4, Column 2

The following publications should be added (following Lowman, H.B., "Affinity maturation of human growth hormone by monovalent phage display", Journal of Molecular Biology, vol. 234, pp. 564-578 (1993)):

--Blazar, Bruce r. et al., "Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 Pathways Is a Highly Effective Means of Preventing Acute Lethal Graft-Versus-Host Disease Induced by Fully Major Histocompatibility Complex-disparate Donor Grafts," Blood, 1995, 85:2607-18 (Exhibit 179)--

--Najafian, et al., "CTLA4-Ig: a novel immunosuppressive agent," Exp. Opin. Invest. Drugs, 2000, 9:2147-2157 (Exhibit 181)--

--Schwartz, R., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy," Cell, 1992, 71:1065-1068 (Exhibit 194)--

In that these errors were incurred by the Office, no fee is believed to be due. If any fee not accounted for is due in connection herewith, please charge such fee to Deposit Account No. 19-3880 of the undersigned.

OCT 16 2000

Please send the Certificate to the address associated with customer account number 23914.

Respectfully submitted,



---

Nickki L. Parlet  
Attorney for Applicant  
Reg. No. 44,996  
Phone: 609-252-5170

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

Date: October 6, 2006

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**Page 1 of 2

PATENT NO. : 7094874

APPLICATION NO.: 09/865,321

ISSUE DATE : 22/AUG/2006

INVENTOR(S) : PEACH ROBERT JAMES, NAEMURA JOSEPH ROY, LINSLEY PETER S., BAJORATH  
JURGEN

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent  
is hereby corrected as shown below:

Column 37, line 44 and 48

"extraceilular" should read --extracellular--

Column 37, line 46

"methionirie" should read --methionine--

Column 39, line 40

"praline" should read --proline--

Column 40, line 3

"CD86than" should read --CD86 than--

Page 1, Column 2, under "Foreign Patent Documents", the following patents should be added:

--WO 01/90122 A2--

--WO 01/54732 A1--

--WO 00/23115--

--WO 96/14865--

Page 2, Column 1, the following publication should be added between Exhibit 49 and Exhibit 51:

--Rajesh et al. (1998) Pharm Sci Supplement S-535. (Exhibit 50)--

Page 3, Column 2

"Exhibit 188" should read --Exhibit 118"--

**MAILING ADDRESS OF SENDER (Please do not use customer number below):**

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**OCT 16 2006**

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**Page 2 of 2

PATENT NO. : 7094874

APPLICATION NO.: 09/865,321

ISSUE DATE : 22/AUG/2006

INVENTOR(S) : PEACH ROBERT JAMES, NAEMURA JOSEPH ROY, LINSLEY PETER S., BAJORATH  
JURGEN

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Page 4, Column 2, the following publications should be added (following Lowman, H.B., "Affinity maturation of human growth hormone by monovalent phage display", Journal of Molecular Biology, vol. 234, pp. 564-578 (1993)):

- Blazar, Bruce r. et al., "Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 Pathways Is a Highly Effective Means of Preventing Acute Lethal Graft-Versus-Host Disease Induced by Fully Major Histocompatibility Complex-disparate Donor Grafts," Blood, 1995, 85-2607-18 (Exhibit 179)--
- Najafian, et al., "CTLA4-Ig: a novel immunosuppressive agent," Exp. Opin. Invest. Drugs, 2000, 9:2147-2157 (Exhibit 181)--
- Schwartz, R., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy," Cell, 1992, 71:1065-1068 (Exhibit 194)--

**MAILING ADDRESS OF SENDER (Please do not use customer number below):**

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**OCT 16 2006**

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**Page 1 of 2

PATENT NO. : 7094874

APPLICATION NO.: 09/865,321

ISSUE DATE : 22/AUG/2006

INVENTOR(S) : PEACH ROBERT JAMES, NAEMURA JOSEPH ROY, LINSLEY PETER S., BAJORATH  
JURGEN

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 37, line 44 and 48

"extraceilular" should read --extracellular--

Column 37, line 46

"methionirie" should read --methionine--

Column 39, line 40

"praline" should read --proline--

Column 40, line 3

"CD86than" should read --CD86 than--

Page 1, Column 2, under "Foreign Patent Documents", the following patents should be added:

--WO 01/90122 A2--

--WO 01/54732 A1--

--WO 00/23115--

--WO 96/14865--

Page 2, Column 1, the following publication should be added between Exhibit 49 and Exhibit 51:

--Rajesh et al. (1998) Pharm Sci Supplement S-535. (Exhibit 50)--

Page 3, Column 2

"Exhibit 188" should read --Exhibit 118--

**MAILING ADDRESS OF SENDER (Please do not use customer number below):**

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**OCT 16 2006**

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 2

PATENT NO. : 7094874

APPLICATION NO.: 09/865,321

ISSUE DATE : 22/AUG/2006

INVENTOR(S) : PEACH ROBERT JAMES, NAEMURA JOSEPH ROY, LINSLEY PETER S., BAJORATH  
JURGEN

It is certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Page 4, Column 2, the following publications should be added (following Lowman, H.B., "Affinity maturation of human growth hormone by monovalent phage display", Journal of Molecular Biology, vol. 234, pp. 564-578 (1993)):

- Blazar, Bruce r. et al., "Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 Pathways Is a Highly Effective Means of Preventing Acute Lethal Graft-Versus-Host Disease Induced by Fully Major Histocompatibility Complex-disparate Donor Grafts," Blood, 1995, 85-2607-18 (Exhibit 179)--
- Najafian, et al., "CTLA4-Ig: a novel immunosuppressive agent," Exp. Opin. Invest. Drugs, 2000, 9:2147-2157 (Exhibit 181)--
- Schwartz, R., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy," Cell, 1992, 71:1065-1068 (Exhibit 194)--

### MAILING ADDRESS OF SENDER (Please do not use customer number below):

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OCT 16 2006